Evidence map›Paper›PMID 35067426›Full record

ArticleZeitschrift fur medizinische Physik2022

Diagnostic Reference Levels for nuclear medicine imaging in Austria: A nationwide survey of used dose levels for adult patients.

David Wachabauer, Thomas Beyer, Manfred Ditto, Hans-Jürgen Gallowitsch, Michael Hinterreiter, Bettina Ibi, Phillipp Malle, Siroos Mirzaei, Florian Smetana, Anton Staudenherz and 3 more

Open access · goldAbstract read
In one paragraph

Article in Zeitschrift fur medizinische Physik, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

David WachabauerAustrian National Public Health Institute (Gesundheit Österreich GmbH (GÖG)), Vienna, Austria. Electronic address: David.wachabauer@goeg.at.
Thomas BeyerQIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University Vienna, Austria; Austrian Society of Nuclear Medicine and Molecular Biology (OGNMB), Vienna, Austria.
Manfred DittoFederal Ministry of Social Affairs, Health, Care and Consumer Protection, Vienna, Austria.
Hans-Jürgen GallowitschAustrian Society of Nuclear Medicine and Molecular Biology (OGNMB), Vienna, Austria; Department of Nuclear Medicine and Endocrinology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.
Michael Hinterreiterrtaustria - Austrian Society of Radiological Technologists, Wiener Neustadt, Austria.
Bettina IbiClinic Hietzing, Institute for Hospital Physics, Vienna, Austria; Austrian Society for Medical Physics (ÖGMP), Vienna, Austria.
Phillipp MalleInstitute of Diagnostic and Interventional Radiology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria; Austrian Roentgen Society, Vienna, Austria.
Siroos MirzaeiAustrian Society of Nuclear Medicine and Molecular Biology (OGNMB), Vienna, Austria.
Florian SmetanaDepartment of Nuclear Medicine and Endocrinology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria; Austrian Society for Medical Physics (ÖGMP), Vienna, Austria.
Anton StaudenherzKarl Landsteiner University of Health Sciences; Department of Nuclear Medicine, University Hospital St. Poelten, Austria; Austrian Society for Radiation Protection in Medicine (VMSÖ), Vienna, Austria.
Boris WarwitzAustrian Society for Medical Physics (ÖGMP), Vienna, Austria; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
Georg ZettinigVienna Thyroid Center Schilddruesenpraxis Josefstadt, Vienna, Austria; Federal Working Group Nuclear Medicine of the Austrian Medical Association, Austria.
Ivo RauschQIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University Vienna, Austria; Austrian Society for Radiation Protection in Medicine (VMSÖ), Vienna, Austria. Electronic address: ivo.rausch@meduniwien.ac.at.
Klinikum Klagenfurt · ATMedical University of Vienna · ATEuropean Association of Nuclear Medicine · ATEuropean Society of Radiology · ATFederal Ministry of Social Affairs, Health, Care and Consumer Protection · ATGesundheit Österreich · ATInnsbruck Medical University · ATKarl Landsteiner University of Health Sciences · ATKlinik Hietzing · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess dose levels in routine nuclear medicine (NUC) procedures in Austria as a prior to a legislative update of the National Diagnostic Reference Levels (NDRL).

methodAs part of a nationwide survey of common NUC-examinations between June 2019 and November 2019, data sets were collected from 33 Austrian hospitals with NUC equipment. All hospitals were asked to report the NUC imaging devices in use (model, type, year of manufacture, detector material, collimators), the standard protocol parameters for selected examinations (standard activity, collimator, average acquisition time, reconstruction type, use of time-of-flight) and to report data from 10 representative examinations (e.g. injected activity, weight), incl. the most common NUC-examinations for planar imaging/SPECT and PET. Median/mean values for injected activity were calculated and compared to current Austrian and international NDRL. A Pearson correlation coefficient was computed comparing different variables.

resultsIn total, all 33 hospitals (100% response rate) reported data for this study for 60 SPECT devices, 21 PET/CT devices and 23 scintigraphy devices. Fixed activity values for scintigraphy/SPECT and PET were employed by about 90% and 56% of the hospitals, respectively. The most widely performed examinations for scintigraphy/SPECT are bone imaging, thyroid imaging, renal imaging (with MAG3/EC) and lung perfusion imaging (in 88% of the hospitals) and F-18 FDG-PET studies for oncology indications (in 100% of the hospitals). Significant correlations were found for patient weight and injected activity (scintigraphy/SPECT), use of iterative reconstruction and injected activity (PET) as well as size of field-of-view and injected activity (PET).

conclusionsThe reported injected activity levels were comparable to those in other countries. However, for procedures for which NDRL exist, deviations in injected activities of >20% compared to the NDRL were found. These deviations are assumed to result mainly from advances in technology but also from deviations between NDRL and prescribed activities as given in the information leaflets of the radiopharmaceuticals.

Indexed as

Nuclear MedicineAdultAustriaDiagnostic Reference LevelsFluorodeoxyglucose F18HumansPositron Emission Tomography Computed TomographyRadiopharmaceuticalsTomography, Emission-Computed, Single-PhotonFluorodeoxyglucose F18RadiopharmaceuticalsDiagnostic reference levelsNuclear medicineRadiation Protection

Identifiers

PMID35067426
PMCPMC9948827
OpenAlexW4206699023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.